Renal Cancer - Results from #1480

The WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. May 23, 2022

Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients' Prognosis With Metastatic Renal Cancer. May 20, 2022

Glutaminase inhibition in renal cell carcinoma therapy. May 20, 2022

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. May 19, 2022

Artificial Intelligence in Kidney Cancer. May 19, 2022

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial. May 18, 2022

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. May 18, 2022

A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients. May 17, 2022

Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. May 17, 2022

Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. May 17, 2022

Multi-Omics Analysis of the Prognosis and Biological Function for TRPV Channel Family in Clear Cell Renal Cell Carcinoma. May 16, 2022

Prognostic Utility of TFCP2-Mediated Genes in Clear Cell Renal Cell Carcinoma Inflammation and Outcome. May 16, 2022

Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. May 13, 2022

ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma. May 13, 2022

Quantifying Absolute Benefit for Adjuvant Treatment Options in Renal Cell Carcinoma: A Living Interactive Systematic Review and Network Meta-analysis. May 12, 2022

Impact of blood transfusion on survival after nephrectomy for localized or locally advanced renal cancer. May 12, 2022

Reproductive and external hormonal factors and the risk of renal cell cancer in the Netherlands Cohort Study. May 11, 2022

Developments in personalized therapy for metastatic renal cell carcinoma. May 11, 2022

A Randomized Ph2 Study of MEDI0680 in Combination With Durvalumab vs. Nivolumab Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma. May 10, 2022

Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities. May 10, 2022

Page 75 of 456